These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 16520359

  • 1. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J, Nomura T, Hirono M, Okubo S, Udagawa K, Shiiki S, Ikeda M, Nakashima K, Tanaka K, Sonoo H.
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [Abstract] [Full Text] [Related]

  • 2. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L, Conte M, Berti P, Miccoli P.
    BMC Cancer; 2006 Nov 20; 6():269. PubMed ID: 17116247
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N, Ragab HM, El Maksoud NA, Shaalan M.
    Cancer Biomark; 2010 Nov 20; 6(2):63-72. PubMed ID: 20571232
    [Abstract] [Full Text] [Related]

  • 4. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M, Peloso L, Mione R, Vignati G, Fortunato A, Saracchini S, Biasioli R, Gulisano M, Cappelli G.
    Cancer J; 2001 Nov 20; 7(3):181-90. PubMed ID: 11419026
    [Abstract] [Full Text] [Related]

  • 5. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
    Sütterlin M, Bussen S, Trott S, Caffier H.
    Anticancer Res; 1999 Nov 20; 19(4A):2567-70. PubMed ID: 10470196
    [Abstract] [Full Text] [Related]

  • 6. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, D'Alessandro R, Carone MD, Cicchetti A, Ricciotti A, Venturo I, Perri P, Di Filippo F, Cognetti F, Botti C, Roselli M.
    Clin Cancer Res; 2001 Aug 20; 7(8):2357-62. PubMed ID: 11489813
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K, Karaki K, Watanabe K, Tsuda H, Konishi F.
    Rinsho Byori; 1993 Oct 20; 41(10):1108-15. PubMed ID: 8254956
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J, Kruszewski WJ, Sliwińska M, Kruszewska E, Hajdukiewicz W, Sliwiński W, Rolka-Stempniewicz G, Góralczyk M, Leśniewski-Kmak K.
    Przegl Lek; 2001 Oct 20; 58(6):498-503. PubMed ID: 11816740
    [Abstract] [Full Text] [Related]

  • 11. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
    Nakamura T, Kimura T, Umehara Y, Suzuki K, Okamoto K, Okumura T, Morizumi S, Kawabata T.
    Surg Today; 2005 Oct 20; 35(1):19-21. PubMed ID: 15622458
    [Abstract] [Full Text] [Related]

  • 12. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
    Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M.
    Anticancer Res; 2004 Oct 20; 24(5B):3221-4. PubMed ID: 15510614
    [Abstract] [Full Text] [Related]

  • 13. CSLEX (Sialyl Lewis X) is a useful tumor marker for monitoring of breast cancer patients.
    Fujita T, Murayama K, Hanamura T, Okada T, Ito T, Harada M, Komatsu A, Koyama H, Kanai T, Maeno K, Mochizuki Y, Hama Y, Ito K, Amano J, Fujimori M.
    Jpn J Clin Oncol; 2011 Mar 20; 41(3):394-9. PubMed ID: 20956388
    [Abstract] [Full Text] [Related]

  • 14. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C.
    J BUON; 2009 Mar 20; 14(3):463-72. PubMed ID: 19810140
    [Abstract] [Full Text] [Related]

  • 15. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y, Imoto S, Kasakura S.
    Rinsho Byori; 1995 Jul 20; 43(7):696-702. PubMed ID: 7674542
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
    Murray A, Willsher P, Price MR, Dixon AR, Robertson JF.
    Anticancer Res; 1997 Jul 20; 17(3C):1945-9. PubMed ID: 9216649
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M, Kataja V, Hämäläinen E, Kosma VM, Penttilä I, Alhava E.
    Anticancer Res; 1997 Jul 20; 17(2B):1231-4. PubMed ID: 9137478
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
    Ogawa Y, Ishikawa T, Ikeda K, Nakata B, Sawada T, Ogisawa K, Kato Y, Hirakawa K.
    Clin Cancer Res; 2000 Oct 20; 6(10):4069-72. PubMed ID: 11051258
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.